1. Germany Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Carl Zeiss Meditec AG

Carl Zeiss Meditec AG

34.98
EUR
+0.94
(+2.76%)
1.42EPS
28.45P/E
3.26BMarket Cap
Dec 10Next Earn
Carl Zeiss Meditec AG
STU:AFX
(Stuttgart Stock Exchange)

Recent

price

34.98

P/E

ratio

28.45

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
8.32
9.33
10.6
11.15
11.18
12.79
13.39
13.9
14.32
16.32
14.93
18.41
21.27
23.36
23.25
25.45
25.66
Revenue per Share
0.73
0.82
0.88
1.13
0.92
0.77
1.21
1.57
1.41
1.79
1.37
2.64
3.29
3.25
2.01
1.61
1.4
Basic EPS, GAAP
0.66
0.33
0.95
0.66
0.55
0.49
1.03
-0.02
1.7
1.93
1.49
3.32
1.19
1.53
1.07
1.52
2.94
Free Cash Flow per Basic Share
0.18
0.55
0.3
0.4
0.45
0.4
0.38
0.44
0.55
0.55
0.65
0.5
0.9
1.1
1.11
0.6
- -
Dividend per Share
7.04
7.37
8.06
8.35
8.8
9.27
9.81
13.59
14.46
15.64
16.01
18.55
22.53
24.14
23.32
24.18
- -
Book Value per Share
5.23
5.68
6.3
6.71
6.33
6.69
7.13
10.87
11.56
10.24
10.74
13.16
15.04
16.59
4.03
5.53
- -
Tangible Book Value per Share
81
81
81
81
81
81
81
86
89
89
89
89
89
89
89
88
86
Basic Weighted Avg Shares
677
759
862
906
909
1,040
1,088
1,190
1,281
1,459
1,335
1,647
1,903
2,089
2,066
2,228
2,204
Sales/Revenue/Turnover
12.81
13.65
14.26
14.63
13.28
12.56
14.18
14.48
15.39
18.14
13.3
22.69
20.86
16.66
9.41
10.02
8.91
Operating Margin (%)
21
19
18
19
18
19
20
24
31
48
60
62
70
74
133
126
- -
Depreciation Expense
60
67
72
92
75
62
98
134
126
160
122
236
294
290
179
141
121
Net Income, GAAP
28.14
28.36
34.25
32.88
30.89
35.55
29.58
27.99
29.55
30.14
30.94
29.95
26.66
29.22
25.21
26.59
27.62
Effective Tax Rate (%)
8.81
8.82
8.34
10.16
8.24
5.99
9.03
11.3
9.87
10.95
9.16
14.35
15.45
13.9
8.65
6.34
5.47
Profit Margin (%)
433
468
495
528
496
533
573
892
971
965
995
1,156
1,253
1,350
639
728
- -
Working Capital
9
24
14
12
10
9
6
3
7
43
53
102
106
134
127
108
- -
LT Debt
599
634
696
715
754
797
851
1,242
1,315
1,417
1,451
1,677
2,030
2,173
2,056
2,128
- -
Total Equity
10.49
11.46
11.49
12
10.92
9.58
12.68
12.2
10.85
13.06
8.11
15.63
14.56
10.84
6.32
7.24
- -
Return on Invested Capital (%)
10.12
10.45
10.31
12.32
9.72
7.72
11.89
12.82
9.99
11.76
9.39
14.56
15.11
13.35
8.79
7.15
- -
Return on Capital (%)
10.9
11.42
11.46
13.81
10.75
8.48
12.67
13.36
10.08
11.87
8.65
15.29
16
13.91
8.51
6.79
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
- -
24
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
108
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
82
Market Capitalization
4,998
3,715
3,263

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
Total Current Assets
- -
1,272
- -
Cash, Cash Equivalents & STI
- -
27
- -
Accounts Receivable, Net
- -
209
- -
Inventories
- -
497
- -
Total Current Liabilities
- -
544
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
24
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.04%
8.36%
3.46%
Free Cash Flow
-1,182.26%
19.28%
40.11%
Net Income, GAAP
14.84%
11.36%
-20.99%
Sales/Revenue/Turnover
8.24%
11.07%
7.82%
Total Cash Common Dividend
- -
6.49%
-46.52%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
475
472
539
580
2,066
2025
491
560
550
628
2,228
2026
467
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.52
0.38
0.69
2.01
2025
0.18
0.52
0.33
0.59
1.61
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Carl Zeiss Meditec AG, a leading medical technology company listed on the MDAX and TecDAX indices of the German stock exchange (AFX.DE), develops and markets innovative technologies and application-oriented solutions for ophthalmology and microsurgery. The company offers one of the most comprehensive product portfolios in ophthalmology, including systems and consumables for cataract and corneal refractive surgery; diagnostic and therapeutic devices for managing chronic eye diseases such as glaucoma and retinal disorders; solutions for posterior eye segment diagnosis and treatment; and digitally connected workflow tools incorporating machine learning and artificial intelligence for data management and automation. In microsurgery, it provides complete visualization solutions for minimally invasive procedures in neurosurgery, ear-nose-throat surgery, spine surgery, plastic and reconstructive surgery, and dentistry. Founded in 2002 as a subsidiary of Carl Zeiss AG through the merger of ZEISS's ophthalmic business with laser technology maker Asclepion Meditec AG, the company is headquartered in Jena, Germany, with significant operations in over 50 countries, including major employee bases in the USA, Japan, Spain, France, India, and China. In April 2024, Carl Zeiss Meditec completed the acquisition of Dutch Ophthalmic Research Center (D.O.R.C.) from Eurazeo SE, integrating D.O.R.C.'s EVA NEXUS platform and vitreoretinal surgery portfolio to enhance its ophthalmic offerings, particularly in retina and posterior segment procedures, and to expand digitally connected end-to-end workflows for surgeons.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q3 2026 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    Carl Zeiss Meditec Q2 Earnings Call Highlights

  • defenseworld.net

    Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Sees Large Increase in Short Interest

  • seekingalpha.com

    Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential

  • defenseworld.net

    Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Receives Average Recommendation of “Hold” from Analysts

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026

  • seekingalpha.com

    Invesco Global Opportunities Fund Q3 2025 Performance Review

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript

  • seekingalpha.com

    Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

  • seekingalpha.com

    Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Recovery Seems Clear Enough

  • seekingalpha.com

    Carl Zeiss: Why I Am So Positive

  • seekingalpha.com

    My 3 Favorite European Stocks To Diversify Your Portfolio

  • seekingalpha.com

    Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows

  • seekingalpha.com

    Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside